Results 101 to 110 of about 6,491 (191)

Evolución de los recién nacidos con aplicación de palivizumab

"El virus sincitial respiratorio infecta las vías y conductos respiratorios con una incidencia del 90% en pacientes menores de 24 meses, de los cuales 40% desarrollan cuadro de bronquiolitis.
García Fuentes, Yamil Dayri
core  

Efficacy and safety of monoclonal antibodies against respiratory syncytial virus disease in premature infants: a systematic review and network meta-analysis. [PDF]

Front Pediatr
Liu S, Wang Y, Cao Y, Song H, Tian Z, Li X, Huang L.   +6 more
europepmc   +1 more source

Post-marketing safety profile of palivizumab: a 20-year pharmacovigilance study using the FDA Adverse Event Reporting System (FAERS). [PDF]

Naunyn Schmiedebergs Arch Pharmacol
Yan Q, Zhong Y.
europepmc   +1 more source

Analysis of the Economic and Public Health Impact of New Immunization Strategies in Infants Against Respiratory Syncytial Virus (RSV) in Colombia. [PDF]

Infect Dis Ther
Carrasquilla-Sotomayor M, Alvis-Zakzuk NJ, Coronell-Rodríguez W, Arias A, Moyano-Tamara L, Alvarado-Gonzalez JC, De la Hoz-Restrepo F, Alvis-Guzman N.   +7 more
europepmc   +1 more source

Advancements in Respiratory Syncytial Virus (RSV) Prevention and Treatment in Pediatrics. [PDF]

J Pediatr Pharmacol Ther
Fly JH, Stultz JS, Eiland LS.
europepmc   +1 more source

Influence of adrenomedullin on the enzymatic activity of dipeptidyl peptidase 3 <i>in vitro</i>. [PDF]

J Enzyme Inhib Med Chem
Nissen R, Yourdkhani A, Hollerbach ML, Seewald K, Santos K, Struck J, Bergmann A.   +6 more
europepmc   +1 more source

Efficacy and effectiveness of long-acting monoclonal antibodies and vaccines against RSV: a systematic review and meta-analysis of studies from 2018 to 2025. [PDF]

EClinicalMedicine
Du J, Li S, Hung IFN, Wu JT, Leung K.
europepmc   +1 more source

Palivizumab prophylaxis and risk of RSV infection among moderate-to-late preterm infants: A nationwide Korean cohort study from 2018 to 2022. [PDF]

Medicine (Baltimore)
So H, Kim Y, Yoon Y, Lee H, Kwon Y, Min J, Kim M, Kim EH, Kim G, Kim YM, Lee B.   +10 more
europepmc   +1 more source

Cost-Effectiveness Analysis of Clesrovimab for Respiratory Syncytial Virus in Infants in the United States. [PDF]

Vaccines (Basel)
Kura K, Lang JC, Wang D, Choi Y, Goveia MG, Sinha A, Chen YH, Elbasha EH.   +7 more
europepmc   +1 more source

Clesrovimab in Infants at Increased Risk For Severe Disease During 2 RSV Seasons: A Randomized Clinical Trial.

JAMA Pediatr
Zar HJ, Bont LJ, Manzoni P, Muñoz FM, Ramilo O, Chen PY, Novoa JM, Ordoñez GA, Tsolia M, Tapiéro B, Acuña-Ávila MI, Castellanos JM, Meyer M, Morioka I, Heinonen S, Chen Z, Zeng T, Railkar RA, Arriola CS, Zang X, Hildebrand C, Maestri A, Castagnini LA, Sinha A, SMART (MK-1654-007) study group.   +24 more
europepmc   +1 more source